http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20040104054-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5ad09028b761c40ad03333afdea62320 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6cc0e0466c846f0a43d38de1bce0be05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dd7c27b9ec61781656e6f039702fd568 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-83 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-04 |
| filingDate | 2003-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60baf7c875499d3bdeb3fe0af7658303 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_688d46c269fdec6278b0e43eae761bfd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9690e28c3bc3c2ffd8b342e863d7607e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7a5b04d0155f66e5bb912cc51153b6b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22dba7b2632a2eb8b9475992ad3adc0e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c49261b7feaa04f52ba3ffda798370b1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a36e7a8a8aa53c9545e47d3ce310056a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f323466f0f82a911496ad63aa7f5c080 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad9ad5473310e3fd8c8280866b659c15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2007dc9b6a69d1927a62577eb7552e3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79d60c470a8674d8860e4686f7d9a047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a9a37d1293925730ee8848fc0880195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da0cff67d42d4498e84b8ae0f4424649 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a607cb8c3d7355af40f77d866abcaac5 |
| publicationDate | 2004-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20040104054-A |
| titleOfInvention | Pyrazolidine derivatives comprising acyl group and pharmaceutical acceptable salts thereof, and method for the preparation thereof |
| abstract | The present invention relates to a pyrazolidine derivative comprising an acyl group represented by the following formula (1), a pharmaceutically acceptable salt thereof, and a preparation method thereof. Since pyrazolidine derivatives containing acyl groups of the present invention inhibit the activity of dipeptidyl peptidase-IV (DPP-IV), pharmaceutical compositions comprising the same are insulin dependent, non-insulin dependent diabetes mellitus mediated by DPP-IV. It is very useful as a therapeutic agent for diseases such as arthritis, obesity, osteoporosis and impaired glucose tolerance:n n n n n n n n n n Wheren n n R 1 is the same as or different from each other hydrogen; halogen; Cyano; Nitro; Hydroxy; Amino; CO 2 H; CONH 2 ; CSNH 2 ; Amidine; An alkyl group of C 1 -C 4 ; Haloalkyl group of C 1 -C 4 ; An alkoxy group of C 1 -C 7 ; An alkylamino group of C 1 -C 4 ; An alkylthio group of C 1 -C 4 ; An alkylamide group of C 1 -C 4 ; An acylamino group of C 1 -C 4 ; An acyloxy group of C 1 -C 4 ; An alkylsulfonamide group of C 1 -C 4 ; Alkyl sulfonate group of C 1 -C 4; Imidic acid C 1 -C 4 alkyl esters; Thioimidic acid C 1 -C 4 alkyl esters; Methyl groups substituted with hydroxy, amino, cyano, morpholine, acetate, acetamide, or methanesulfonamide groups; A C 1 -C 4 haloalkyl group, a C 1 -C 4 alkoxy group, or a phenyl group substituted with halogen; Or a C 1 -C 4 haloalkyl group, a C 1 -C 4 alkoxy group, or a benzyloxy group substituted with halogen;n n n m is 1 or 2;n n n n is 0 or 1;n n n X is O, S, or N-CN;n n n ACO represents the following formula (2) or (3),n n n n n n n n n n n n n n n n n Where R 2 is a general substituent of amino acids: alanine, arginine, aspartic acid, cysteine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, metaionine, phenylalanine, proline, hydroxyproline , Serine, threonine, tryptophan, tyrosine, valine, cyclohexylglycine, threonine, isoleucine-isoleucine, isoleucine-valine, valine-isoleucine, proline-isoleucine, or isoleucine-proline A substituent present at R 3 is an alkyl group of C 1 -C 6 ; A cycloalkyl group of C 5 -C 8 substituted with hydrogen or a benzoylamino group; An adamantyl group substituted with hydrogen or hydroxy; Morpholine, or piperazine substituted with an alkyl group of C 1 -C 4 ; Piperidine substituted with an hydroxy or C 1 -C 4 alkyl group; Or ethylamino pyridine substituted with a cyano, halogen, nitro, or haloalkyl group of C 1 -C 4 . |
| priorityDate | 2003-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 271.